Novartis AG Common Stock (NY:NVS)

The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets

January 07, 2026

The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of...

The cloud stock gained after a better-than-expected earnings report.

Why Salesforce Rose 16% in December ↗

January 07, 2026

Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals ↗

Topics Artificial Intelligence

January 01, 2026

Via Chartmill

Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗

January 07, 2026

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Topics Government

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

Topics Economy Intellectual Property Stocks

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...

The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery

Topics Artificial Intelligence

January 01, 2026

The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...

The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI...

Topics Artificial Intelligence

Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine

December 31, 2025

Compare how fund size, holdings, and portfolio breadth set VEA and SPDW ETFs apart for diversified investors.

Topics Artificial Intelligence Bonds

Invest Outside the U.S. With These Top International ETFs ↗

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Topics ETFs

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗

Topics Artificial Intelligence ETFs Economy

December 31, 2025

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier

Topics Economy Government

December 30, 2025

As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the...

In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides...

Topics Artificial Intelligence

AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era

December 29, 2025

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Artificial Intelligence Climate Change

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Novartis (NVS) presents a classic value investing case: a financially strong pharmaceutical leader trading at a discount to peers, with high profitability and a solid dividend.

Topics ETFs Intellectual Property

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ↗

December 29, 2025

Via Chartmill

The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine

December 25, 2025

In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was...

Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗

Topics Artificial Intelligence Initial Public Offering

December 23, 2025

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Topics Stocks

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Both have crushed the market this year.

Topics ETFs Economy Intellectual Property

2 Top Stocks to Buy and Hold for the Long Term ↗

December 22, 2025

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics Intellectual Property

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Topics Government World Trade

Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗

December 19, 2025

Via Investor's Business Daily

Topics Government Stocks

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.

Topics Economy Government

White House Readies Drug Price Deals With AbbVie, Novartis, Roche ↗

December 18, 2025

Via Benzinga

Salesforce Stock Rises On BTIG Buy Rating And Novartis Agentforce Deal ↗

December 17, 2025

Salesforce Inc (NYSE:CRM) shares moved higher Wednesday after BTIG kicked off coverage with a Buy rating and a $335 price target, while the company scored a major win with Novartis choosing its...

Via Benzinga

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ↗

Topics Government World Trade

December 10, 2025

Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts.

Via Chartmill

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder ↗

December 09, 2025

Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients.

Via Benzinga

Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025

December 09, 2025

As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical...